STAT+: Pharma showers Menendez with rare, off-cycle burst of campaign cash as Democrats eye drug pricing reforms 

WASHINGTON — Sen. Bob Menendez doesn’t face reelection until 2024, but pharmaceutical executives are already flooding his campaign with cash — a sign of the central role he will play in deciding whether Democrats are able to pass substantial drug pricing reforms this year.

Since March, the New Jersey Democrat has received at least $1,000 from each of the CEOs of eight different drug companies: Pfizer, Merck, Eli Lilly, Bristol Myers Squibb, Genentech, UCB, Otsuka, and Sage Therapeutics, according to federal election disclosures. The Pfizer and Merck executives both personally gave Menendez $5,000 and $5,800, respectfully. Top executives from Amgen and Lundbeck also wrote Menendez personal checks totaling $1,000 and $1,500.

Continue to STAT+ to read the full story…